Trial Profile
A Randomized, Open-label, Crossover Clinical Study to Assess the Safety and the Pharmacokinetic Characteristics of INT-2150 After Oral Administration to Healthy Adult Male Subjects
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs INT-2150 (Primary) ; Irsogladine; Nizatidine
- Indications Gastritis
- Focus Pharmacokinetics
- Sponsors Kukje Pharma
- 04 May 2018 New trial record